Artes Medical to Present at Lazard Capital Markets
Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--Nov. 20, 2007--Artes Medical, Inc. (Nasdaq:
ARTE), a medical technology company whose product ArteFill(R)
is the first and only FDA-approved non-resorbable injectable dermal filler for the correction of nasolabial fold or "smile line" wrinkles, today
announced it will present at the Lazard Capital
Markets Healthcare Conference on Tuesday, November 27, 2007 at 9:30 a.m.,
Eastern Time, at The Palace Hotel in New York City.
A live audio webcast of the presentation at Lazard Capital Markets Healthcare Conference will be
accessible through Artes Medical's
investor relations web site at http://ir.artesmedical.com. An archived edition
of the presentation will be available later that day and archived for 180 days.
Diane S. Goostree, President and Chief Executive
Officer, will provide a corporate overview of the Company. Artes
Medical's news releases and other information about
the Company and its FDA-approved product, ArteFill,
are available on its web site at www.artesmedical.com.
About ArteFill(R)
ArteFill is the first and only FDA-approved non-resorbable injectable dermal
filler for the correction of wrinkles known as smile lines or nasolabial folds. The unique microspheres
in ArteFill are not absorbed
by the body and therefore provide the first-of-its-kind permanent support for
long-lasting wrinkle correction in one to two treatments.
ArteFill was approved by the FDA in October 2006
based on data from the Company's 12-month controlled, randomized,
double-masked, multi-center U.S. clinical trial, which compared outcomes for
patients treated with ArteFill with those of patients
treated with the leading bovine collagen-based filler. At the 6-month
evaluation, which was the primary efficacy evaluation period for the clinical
trial, the wrinkle correction in patients treated with ArteFill
persisted and showed statistically significant improvement compared to the
wrinkle correction in the patients treated with the collagen control, who
returned to their pretreatment status. The ArteFill
patients were also evaluated one year after treatment,
demonstrating continued safety and wrinkle correction. In February 2007, the
Company announced it completed a 5-year follow-up study of 145 patients who were treated with ArteFill in the
Company's
In addition to demonstrating the safety profile of ArteFill,
the study showed statistically significant (p less than 0.001) improvement in
patient wrinkle correction five years after the patient's last ArteFill treatment, and a statistically significant
(p=0.002) improvement in wrinkle correction at the 5-year point compared to the
6-month evaluation period. As part of the study, physician investigators and
patients were asked to provide their assessment of ArteFill treatment. Over 90% of the physician assessments
were either "completely successful" or "very successful;"
and over 90% of the patient assessments were either "very satisfied"
or "satisfied." In March 2007, the Company submitted the data from
the study to the FDA for review in order to enhance the product labeling for ArteFill.
An ArteFill Skin Test is required before initial
treatment. The most common adverse events associated with ArteFill
treatment, similar to those observed with other dermal fillers, are lumpiness,
persistent swelling or redness and increased
sensitivity at the injection site.
ArteFill is a proprietary formulation comprised of
polymethylmethacrylate, or PMMA, microspheres
and bovine collagen, and is the only PMMA-based injectable
product that has been approved by the FDA for the
treatment of facial wrinkles. Artes Medical is the
sole manufacturer of ArteFill, which is only
available in the
About Artes Medical, Inc.
Artes Medical is a medical technology company focused
on developing, manufacturing and commercializing a new category of aesthetic injectable products for the dermatology and plastic surgery
markets. There were approximately two million dermal filler procedures in the
Artes Medical(R) and ArteFill(R)
are registered trademarks of Artes Medical, Inc.
CONTACT: Investor Relations:
Artes
Medical, Inc.
Cheryl Monblatt Allen, 858-550-9999
callen@artesmedical.com
or
Media:
Schwartz Communications, Inc.
Thea Lavin, 415-512-0770
artes@schwartz-pr.com
SOURCE: Artes Medical, Inc.